Kiniksa Pharmaceuticals International (KNSA) Total Liabilities (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Total Liabilities came in at $242.0 million in Q2 2026, up 45.63% YoY from $166.1 million in Q2 2025, and up 10.19% on a QoQ basis from $219.6 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Total Liabilities (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Total Liabilities data on file, last reported at $242.0 million in Q2 2026.
- Quarterly Total Liabilities rose 45.63% year-over-year to $242.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $242.0 million (up 45.63% YoY) and the FY2025 annual result came in at $196.0 million, up 37.93% from the prior year.
- Total Liabilities climbed to $242.0 million in Q2 2026, from $219.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $242.0 million in Q2 2026 to a low of $52.8 million in Q1 2023.
- A 5-year average of $119.5 million and a median of $97.6 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 95.68% — and 2023, when it slipped 18.47%.
- Tracing KNSA's Total Liabilities over 5 years: stood at $63.5 million in 2022, then jumped by 37.72% to $87.5 million in 2023, then soared by 62.45% to $142.1 million in 2024, then soared by 37.93% to $196.0 million in 2025, then advanced by 23.43% to $242.0 million in 2026.
- The last three Total Liabilities figures came in at $242.0 million (Q2 2026), $219.6 million (Q1 2026), and $196.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 2.12 Bn |
| 10 | Kiniksa Pharmaceuticals International | 6.04 Bn | 5.52 Bn | 220.03 Mn | 241.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 241.96 Mn |
| Mar 31, 2026 | 219.59 Mn |
| Dec 31, 2025 | 196.03 Mn |
| Sep 30, 2025 | 176.95 Mn |
| Jun 30, 2025 | 166.14 Mn |
| Mar 31, 2025 | 141.84 Mn |
| Dec 31, 2024 | 142.12 Mn |
| Sep 30, 2024 | 118.29 Mn |
| Jun 30, 2024 | 107.33 Mn |
| Mar 31, 2024 | 87.78 Mn |
| Dec 31, 2023 | 87.48 Mn |
| Sep 30, 2023 | 77.94 Mn |
| Jun 30, 2023 | 72.68 Mn |
| Mar 31, 2023 | 52.77 Mn |
| Dec 31, 2022 | 63.52 Mn |
| Sep 30, 2022 | 75.95 Mn |
| Jun 30, 2022 | 57.08 Mn |
| Mar 31, 2022 | 64.72 Mn |
| Dec 31, 2021 | 47.76 Mn |
| Sep 30, 2021 | 38.81 Mn |